Barakat Eman F, Sherief Ahmed F, Elsheikh Nesma G, Khalifa Mai Mohi M El-Metwaly
Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Geriatric and Gerontology Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Egypt Liver J. 2023;13(1):27. doi: 10.1186/s43066-023-00262-y. Epub 2023 May 23.
Reactivation of herpesviruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in COVID-19 patients reported in many studies in different countries during the pandemic. We aimed to measure prevalence of this coinfection in Egyptian COVID-19 patients with elevated liver enzymes and its relation to the severity and the outcome of COVID-19 infection in those patients.
A cross-sectional study was carried out on 110 COVID-19 patients with elevated liver enzymes regardless the severity of COVID-19 disease. All patients were subjected to medical history, clinical examination, laboratory investigations, high-resolution computed tomography chest (HRCT chest). Epstein-Barr virus (EBV) and Human cytomegalovirus (HCMV) were determined by VCA IgM and CMV IgM respectively by enzyme-linked immunosorbent assay (ELISA).
Of the included 110 patients with COVID-19 illness, 5 (4.5%) were Epstein-Barr virus seropositive and 5 (4.5%) were human cytomegalovirus seropositive. Regarding the symptoms, the incidence of fever in the EBV and CMV seropositive group was apparently higher than that in the EBV and CMV seronegative group. In lab tests, the platelets and albumin of EBV and CMV seropositive group decreased more significantly than EBV and HCMV seronegative group, and serum ferritin, D-dimer, and C-reactive protein show higher values in seropositive group than in seronegative group but not statistically significant. Seropositive group had received higher doses of steroids than seronegative group. The median of hospital stay in seropositive group was (15 days) nearly double that of seronegative group with statistically significant difference between both groups.
Coinfection of EBV and CMV in COVID-19 Egyptian has no effect on the disease severity or the clinical outcome of the disease. But those patients had higher hospital stay duration.
在疫情大流行期间，不同国家的许多研究报告了新冠病毒疾病（COVID-19）患者中爱泼斯坦-巴尔病毒（EBV）和巨细胞病毒（CMV）等疱疹病毒的重新激活情况。我们旨在测定埃及肝功能酶升高的COVID-19患者中这种合并感染的患病率，及其与这些患者中COVID-19感染的严重程度和结局的关系。
对110例肝功能酶升高的COVID-19患者进行了一项横断面研究，不考虑COVID-19疾病的严重程度。所有患者均接受病史采集、临床检查、实验室检查、胸部高分辨率计算机断层扫描（HRCT胸部）。分别通过酶联免疫吸附测定（ELISA）法，用VCA IgM和CMV IgM测定爱泼斯坦-巴尔病毒（EBV）和人巨细胞病毒（HCMV）。
在纳入的110例COVID-19患者中，5例（4.5%）爱泼斯坦-巴尔病毒血清学阳性，5例（4.5%）人巨细胞病毒血清学阳性。关于症状，EBV和CMV血清学阳性组的发热发生率明显高于EBV和CMV血清学阴性组。在实验室检查中，EBV和CMV血清学阳性组的血小板和白蛋白下降比EBV和HCMV血清学阴性组更显著，血清铁蛋白、D-二聚体和C反应蛋白在血清学阳性组中的值高于血清学阴性组，但无统计学意义。血清学阳性组接受的类固醇剂量高于血清学阴性组。血清学阳性组的住院中位数为（15天），几乎是血清学阴性组的两倍，两组之间有统计学意义的差异。
埃及COVID-19患者中EBV和CMV合并感染对疾病严重程度或疾病临床结局无影响。但这些患者的住院时间更长。
